Medicare spent more on skin substitutes in 2024 than on almost any drug in its formulary. Most of the products have no clinical trials. Some were applied to dying hospice patients by untrained sales reps. Here's how a quiet corner of wound care became the fastest-growing fraud category in Medicare history.
Let's start with the number that made Congress choke on its coffee. In 2019, Medicare Part B spent $256 million on a category of wound-care products called "skin substitutes" — thin membranes, mostly derived from donated human placental tissue, applied to chronic wounds like diabetic foot ulcers. By 2024, that figure had exploded to over $10.2 billion, according to MedPAC's July 2025 Data Book. The number of patients treated roughly doubled. The price per treatment nearly 20×'d.
To put that in context: skin substitutes, a product category most Americans have never heard of, became the single largest therapeutic class in Medicare Part B by 2024, surpassing cancer drugs and eye injections. They consumed more than 15% of all Part B drug spending. The Congressional Budget Office projected that the new payment reforms would save $245 billion over the next decade — which tells you everything about the scale of the overpayment.
The HHS Inspector General called the growth "unprecedented" and flagged "major concerns about fraud, waste, and abuse." The DOJ has indicted dozens. One Arizona couple was sentenced to a combined 29.5 years in prison for a $1.2 billion scheme that applied unnecessary wound grafts to hospice patients in their final days. And still, the spending kept climbing — reaching an annualized pace of $15.4 billion by mid-2025.
This is the story of how it happened.
The mechanics of the skin substitute gold rush are simple enough that you could explain them at a dinner party, and outrageous enough that no one would believe you.
Medicare Part B pays for physician-administered drugs and biologicals at a formula called ASP + 6% — the manufacturer's average sales price, plus a 6% markup. For a $50 vial of a common drug, that's a rounding error. For a skin substitute billed at $2,979 per square centimeter — as one product, AmnioAMP-MP (Q4250), was priced — the 6% add-on alone is $179 per square centimeter. A single patient treatment of 82 square centimeters (the OIG-reported Q3 2024 average) would generate $244,278 in Medicare payment for the product alone — before the doctor bills for the procedure itself.
But the real trick was the private-label loophole. Most skin substitutes are regulated under Section 361 of the Public Health Service Act as human tissue products, not drugs. That means no clinical trials, no FDA efficacy review — just a demonstration of "minimal manipulation" and "homologous use." A tissue processor could take the same donated amniotic membrane, vary the processing slightly, slap on a new brand name, and apply to CMS for a brand-new HCPCS Q-code. Each new code launched at a new, higher price — often without any ASP history.
The final ingredient was the place-of-service arbitrage. In hospital outpatient departments, skin substitute costs were bundled into the procedure payment. But in physician offices (Place of Service 11), Medicare paid for the product separately, at ASP + 6%, on top of the procedure fee. Manufacturers offered providers discounts of 40-45% off list price, but Medicare paid the full ASP. The spread was a major profit driver. The vast majority of skin substitute use shifted to physician offices — and eventually to patients' homes, where the OIG found costs were 4× higher per patient than in office settings.
Skin substitute spending isn't evenly distributed across the country. Querying CMS Medicare Part B provider-level data for 2023 in FraudGraph for Q4262 (Dual Layer Impax Membrane), one of the highest-spend products, reveals an extreme geographic concentration.
Arizona alone accounted for $526 million — 63% of all national Q4262 spending — from just 12 providers. Most of those providers were nurse practitioners. The single highest biller, Ira Denny, NP, submitted Q4262 claims associated with $135 million in Medicare payment for 90 patients — an average of $1.5 million per patient. Denny was subsequently charged by the DOJ in the June 2025 healthcare fraud takedown.
| Provider | State | Specialty | Beneficiaries | Est. Medicare Payment | $/Patient |
|---|---|---|---|---|---|
| Ira Denny [indicted Jun 2025] | AZ | Nurse Practitioner | 90 | $135,160,596 | $1,501,784 |
| Provider B | AZ | Nurse Practitioner | 97 | $123,792,249 | $1,276,209 |
| Provider C | AZ | Podiatry | 119 | $83,663,242 | $702,884 |
| Provider D | AZ | Nurse Practitioner | 66 | $62,886,995 | $952,833 |
| Provider E | AZ | Nurse Practitioner | 38 | $42,318,310 | $1,113,640 |
Source: CMS Medicare Physician & Other Practitioners by Provider and Service, 2023, queried via FraudGraph. HCPCS Q4262 only.
That said, the concentration itself is striking: 12 providers in one state, billing one product code, generating two-thirds of national spending. And the geographic concentration maps directly to the largest skin substitute prosecution in U.S. history. Alexandra Gehrke and Jeffrey King, a Phoenix couple who operated Apex Medical LLC and related shell companies, pled guilty to a $1.2 billion fraud scheme. Over roughly 18 months in 2022–2024, they submitted false claims for medically unnecessary wound grafts applied to elderly and terminally ill patients, including people in hospice. According to the DOJ, sales reps with no medical training identified patients in nursing homes, determined treatment frequency, and directed nurse practitioners on what to apply. Gehrke and King received $279 million in kickbacks from an allograft distributor. They were arrested attempting to flee at Phoenix Sky Harbor airport. In December 2025, Gehrke was sentenced to 15.5 years; King to 14 years. The judge called them "criminally greedy."
The fraud cases get the headlines, but the policy story is equally damning. CMS has been trying to rein in skin substitute spending since at least 2022. Every attempt has been delayed, diluted, or derailed.
Medicare Administrative Contractors (MACs) first finalized Local Coverage Determinations restricting skin substitute coverage in August 2023. They placed roughly 130 products on a non-covered list and capped applications at 4 per 12-week episode. Within weeks, after intense industry pushback, the MACs withdrew the LCDs entirely. New LCDs were finalized in November 2024, set for February 2025 — then delayed to April 2025 by the Trump administration's regulatory freeze, then delayed again to January 2026, and finally withdrawn entirely on December 24, 2025 — a Christmas Eve gift to the industry.
Meanwhile, the industry fought the payment reforms with campaign cash. Extremity Care, a Virginia-based manufacturer of placental tissue allografts, donated $5 million to MAGA Inc., Trump's super PAC, on February 24, 2025. Six days later, Trump posted on Truth Social criticizing the Biden-era skin substitute rule. Extremity Care's parent company, Tiger BioSciences, also contributed $2.5 million toward White House ballroom construction and retained Ballard Partners — led by top Trump fundraiser Brian Ballard — at $710,000 over 18 months. Total documented political spending by Extremity Care/Tiger BioSciences: over $10.5 million. (None of these expenditures are themselves unlawful; they are documented in FEC filings and federal lobbying disclosures.)
Extremity Care and Legacy Medical Consultants (Fort Worth, TX) co-led the Medicare Access to Skin Substitutes (MASS) Coalition, arguing publicly that CMS's flat-rate payment would limit patient access. A Fierce Healthcare investigation reported on industry rebate practices: list prices set well above the discounts offered to physicians, creating a spread between acquisition cost and Medicare reimbursement. The arrangement is the structural feature CMS's 2026 payment reform is designed to eliminate.
The DOJ has responded to the spending explosion with an increasingly aggressive enforcement campaign. The cases below are all matters of public record — settlements, guilty pleas, or sentences:
| Date | Case | Amount | Outcome |
|---|---|---|---|
| Apr 2020 | MiMedx Group (false pricing disclosures) | $6.5M | FCA settlement |
| Apr 2023 | OK podiatrist (excessive skin substitute claims, VA) | $7M | FCA settlement |
| Apr 2023 | Beverly Hills plastic surgeon (skin graft fraud) | $24M | Settle + 15yr exclusion |
| Jun 2025 | National Healthcare Fraud Takedown (skin subs featured) | $1.1B+ | 324 defendants charged |
| Jul 2025 | Las Vegas NP (fraudulent wound allografts) | $14.3M | Guilty plea |
| Nov 2025 | Vohra Wound Physicians (upcoding debridement) | $45M | FCA settlement + 5yr CIA |
| Dec 2025 | Gehrke/King, Apex Medical (AZ wound graft scheme) | $1.2B | 15.5 & 14 yrs prison |
The Gehrke/King case was what the DOJ called "the first prosecution of its kind" for skin substitute fraud. But it likely won't be the last. Deputy Attorney General Brenna Jenny stated publicly that there are "a lot more skin substitute cases in the pipeline." The False Claims Act statute of limitations extends up to 10 years, meaning billing from 2020 through today remains within scope.
CMS has stood up its own defenses. Its Fraud Defense Operations Center stopped $185 million in improper skin substitute payments in 2025, including one case involving $4.3 million in charges for a single patient with no evidence of prior wound treatment. And the new WISeR (Wasteful and Inappropriate Services Reduction) Model, launched January 2026 in six states (Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington), uses AI-powered prior authorization specifically for skin substitutes.
Looking at how skin substitute companies appear across federal enforcement, regulatory, and disclosure databases reveals patterns that wouldn't surface from any single source. All of the following are matters of public record:
MiMedx Group's enforcement trail spans three federal programs. Cross-referencing SEC enforcement actions, DOJ FCA settlements, and federal court dockets in FraudGraph, MiMedx Group appears in: (i) a $1.5M SEC settlement (2019) for revenue fraud and improper accounting; (ii) the criminal convictions of former CEO Parker Petit and former COO Bill Taylor; (iii) a $6.5M FCA settlement (2020) for false pricing disclosures to the VA; and (iv) at least one ongoing qui tam case alleging Anti-Kickback Statute violations. Three federal enforcement programs (SEC, DOJ Criminal, DOJ Civil/FCA), one corporate entity, all linked through FraudGraph's entity resolution.
Vohra Wound Physicians and the SNF connection. The Vohra $45M FCA settlement bridges wound care fraud with the nursing home industry. Vohra contracted with hundreds of skilled nursing facilities nationwide — the same setting where the OIG found skin substitute utilization grew from 7% to 12.5% of claims between 2023 and 2024. The settlement covered allegations of upcoded debridement procedures, not skin substitutes specifically, but the network of provider relationships is the same one through which skin substitutes are increasingly billed.
The political-spending-and-policy timeline. Combining FEC contribution data, federal lobbying disclosure (LDA) filings, and the Federal Register's regulatory action timeline yields a documented sequence: the Extremity Care/Tiger BioSciences $5M MAGA Inc. donation on February 24, 2025; Trump's Truth Social post six days later criticizing the Biden-era skin substitute rule; the regulatory freeze that followed; the LCD effective date being pushed from February 2025, to April 2025, to January 2026; and the ultimate withdrawal on December 24, 2025. None of those data points alone proves causation, but the sequence is what FraudGraph is built to surface.
As of January 1, 2026, CMS's payment reform is in effect. The old ASP + 6% product-by-product payment is gone for most skin substitutes. In its place: a flat rate of $127.14 per square centimeter, regardless of product. CMS estimates this will reduce spending by $19.6 billion in 2026 — roughly a 90% reduction from the projected trajectory. The payment is now site-neutral, eliminating the physician office arbitrage.
But three things bear watching. First, the LCDs were withdrawn. That means the payment reform caps the price, but there are still no national coverage restrictions specifying which products are evidence-based, how many applications are appropriate, or which patients are suitable candidates. Providers can still apply unlimited quantities of non-evidence-based products — they'll just get $127 instead of $2,979 per square centimeter.
Second, legal challenges are coming. The MASS Coalition and individual manufacturers have signaled they may challenge the reclassification of skin substitutes from "biologicals" to "incident-to supplies." If a court injunction pauses the rule, spending could snap back immediately.
Third, watch for the next iteration of the loophole. The wound-care fraud ecosystem has shown remarkable adaptability. When one product's ASP eroded, manufacturers launched "new" products. When LCDs restricted coverage in certain MAC jurisdictions, billing shifted to unrestricted ones. The OIG documented products that went from $0 to $542 million in a single quarter and then crashed — a hit-and-run pattern that, in the OIG's words, suggests organized, pre-planned billing schemes.